IRIS
VALENTINI, Gabriele
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 24.264
NA - Nord America 8.590
AS - Asia 6.090
SA - Sud America 1.248
Continente sconosciuto - Info sul continente non disponibili 615
AF - Africa 82
OC - Oceania 5
Totale 40.894
Salva come PNG Salva come JPEG
Nazione #
RU - Federazione Russa 9.710
US - Stati Uniti d'America 8.379
IT - Italia 8.162
SG - Singapore 2.333
IE - Irlanda 1.852
CN - Cina 1.265
UA - Ucraina 1.126
BR - Brasile 1.080
HK - Hong Kong 1.046
GB - Regno Unito 854
DE - Germania 632
FR - Francia 584
VN - Vietnam 531
FI - Finlandia 320
NL - Olanda 294
SE - Svezia 253
TR - Turchia 220
GR - Grecia 199
IN - India 167
KR - Corea 165
CA - Canada 129
JP - Giappone 85
BE - Belgio 71
AR - Argentina 57
ES - Italia 52
BD - Bangladesh 47
ID - Indonesia 47
MX - Messico 40
IQ - Iraq 34
CH - Svizzera 33
EC - Ecuador 33
PL - Polonia 31
AT - Austria 26
ZA - Sudafrica 25
CO - Colombia 21
PK - Pakistan 17
UZ - Uzbekistan 17
PY - Paraguay 16
VE - Venezuela 15
TH - Thailandia 14
EG - Egitto 12
EU - Europa 12
MA - Marocco 12
RO - Romania 11
SA - Arabia Saudita 11
AE - Emirati Arabi Uniti 10
CL - Cile 10
TW - Taiwan 10
CZ - Repubblica Ceca 9
HR - Croazia 9
HU - Ungheria 9
KZ - Kazakistan 9
UY - Uruguay 9
CR - Costa Rica 8
KE - Kenya 8
TN - Tunisia 8
AZ - Azerbaigian 6
PE - Perù 6
PH - Filippine 6
BH - Bahrain 5
BY - Bielorussia 5
DZ - Algeria 5
IR - Iran 5
JO - Giordania 5
NI - Nicaragua 5
NP - Nepal 5
PA - Panama 5
TT - Trinidad e Tobago 5
AU - Australia 4
BB - Barbados 4
GT - Guatemala 4
IL - Israele 4
JM - Giamaica 4
KG - Kirghizistan 4
MY - Malesia 4
XK - ???statistics.table.value.countryCode.XK??? 4
DK - Danimarca 3
ET - Etiopia 3
HN - Honduras 3
LK - Sri Lanka 3
MK - Macedonia 3
OM - Oman 3
PT - Portogallo 3
RS - Serbia 3
SN - Senegal 3
AL - Albania 2
AP - ???statistics.table.value.countryCode.AP??? 2
LB - Libano 2
LT - Lituania 2
MN - Mongolia 2
NO - Norvegia 2
QA - Qatar 2
SV - El Salvador 2
SY - Repubblica araba siriana 2
AO - Angola 1
BG - Bulgaria 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BW - Botswana 1
BZ - Belize 1
Totale 40.285
Salva come PNG Salva come JPEG
Città #
Moscow 3.441
Dublin 1.844
Jacksonville 1.576
Hong Kong 1.039
Santa Clara 871
Singapore 826
Chandler 756
San Jose 669
Rome 537
Ashburn 521
Milan 444
Princeton 288
Medford 254
Beijing 225
Ho Chi Minh City 203
Naples 176
Ann Arbor 166
Seoul 160
Council Bluffs 159
Napoli 156
San Mateo 152
Boardman 148
Roxbury 148
Wilmington 138
Hefei 126
Hanoi 123
Bremen 113
Woodbridge 113
Bengaluru 100
Turin 96
Florence 93
Palermo 91
Cambridge 83
Dallas 81
São Paulo 70
Bologna 68
Catania 66
Bari 65
Des Moines 65
Mountain View 64
Brussels 62
Caserta 58
Helsinki 58
The Dalles 55
New York 52
Ottawa 52
Padova 50
Nanjing 49
Verona 43
Genoa 37
Los Angeles 36
Munich 33
Da Nang 31
Rio de Janeiro 31
Cagliari 28
Torino 27
Brasília 26
Pescara 26
Belo Horizonte 25
Messina 24
Taranto 24
Venice 24
Vicenza 24
Houston 23
Mcallen 23
Orem 23
Tokyo 23
Frankfurt am Main 22
Toronto 22
Atlanta 21
Jinan 21
Modena 21
Nuremberg 21
Redwood City 21
Brescia 20
Guangzhou 20
Livorno 20
Parma 20
Perugia 20
Haiphong 19
Salerno 19
France 18
Genova 18
London 18
Baghdad 17
Düsseldorf 17
Kunming 17
Montreal 17
Norwalk 17
Trieste 17
Reggio Emilia 16
Changsha 15
Curitiba 15
Gorno 15
Shanghai 15
Trento 15
Auburn Hills 14
Chicago 14
Mumbai 14
Reggio Calabria 14
Totale 17.871
Salva come PNG Salva come JPEG
Nome #
ARTRITE PSORIASICA ED INTERSTIZIOPATIA POLMONARE : DESCRIZIONE DI UN CASO CLINICO. 8.734
Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: Results of the EUSTAR group 447
ANTI TNF ALFA IN PAZIENTI AFFETTI DA ARTRITE REUMATOIDE E SPONDILOARTRITI HBV CARRIERS OCCULTI:STUDIO RETROSPETTIVO SULLA SICUREZZA 304
A PILOT STUDY ON LOW-DOSE INTRAVENOUS CICLOPHOSPHAMIDE IN SYSTEMIC SCLEROSIS: EFFICACY, SAFETY AND EFFECTS ON CELLULAR ACTIVATION MARKERS 212
Diagnostic issues faced by a rare disease healthcare network during Covid-19 outbreak: data from the Campania Rare Disease Registry 206
Clinical and subclinical atherosclerosis in systemic sclerosis: consequences of previous corticosteroid treatment. 200
Antinuclear antibodies in first-degree relatives of patients with polymyositis-dermatomyositis: analysis of the relationship with HLA haplotypes 189
ANTI-TNFα TREATMENT IS ASSOCIATED WITH INCREASED LIVER STIFFNESS IN HBV OCCULT CARRIER PATIENTS 188
Association between a stromal cell-derived factor 1 (SDF-1/CXCL12) gene polymorphism and microvascular disease in systemic sclerosis 187
Clinical correlates of human leukocyte antigen-G (HLA-G) in systemic sclerosis. 168
[Comparison between auranofin and chloroquine in the therapy of rheumatoid arthritis] 167
[HAQ-DI Italian version in systemic sclerosis]. 166
[T-lymphocyte subpopulations in the conjunctiva of subjects with secondary Sjogren's syndrome] 165
CXCL4 in undifferentiated connective tissue disease at risk for systemic sclerosis (SSc) (previously referred to as very early SSc) 158
Early systemic sclerosis: Analysis of the disease course in patients with marker autoantibody or capillaroscopic positivity or both. 157
Early Systemic Sclerosis: Marker Autoantibody Positive Patients Have A Faster Pace Of The Disease. 156
Alterazione del riempimento ventricolare sinistro nella sclerosi sistemica (SSc): risultati di uno studio Iongitudinale 153
Adult-onset Still's disease: an Italian multicentre retrospective observational study of manifestations and treatments in 245 patients 153
Association of a functional polymorphism in the matrix metalloproteinase-12 promoter region with systemic sclerosis in an Italian population 152
-238 and +489 TNF-alpha along with TNF-RII gene polymorphisms associate with the diffuse phenotype in patients with Systemic Sclerosis 152
Adult-onset Still's disease: Evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers 151
ACE inhibitors in SSc patients display a risk factor for scleroderma renal crisis-a EUSTAR analysis. 151
Assessment of intestinal permeability and orocecal transit time in patients with systemic sclerosis 150
Longterm Hydroxychloroquine Therapy and Low-dose Aspirin May Have an Additive Effectiveness in the Primary Prevention of Cardiovascular Events in Patients with Systemic Lupus Erythematosus 148
.ANTI-TNF alfa IN PATIENTS WITH EITHER RHEUMATOID ARTHRITIS OR SPONYLOATHRITIS And CONCURRENT C HEPATITIS:A RETROSPECTIVE RECORD REVIEW ON SAFETY 147
ARTHRITIS IS ASSOCIATED WITH PSORIASIS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES 147
[Survival and death causes in 251 systemic sclerosis patients from a single Italian center]. 146
Early systemic sclerosis: marker autoantibodies and videocapillaroscopy patterns are each associated with distinct clinical, functional and cellular activation markers. 146
[Atherosclerosis and rheumatoid arthritis: relationships between intima-media thickness of the common carotid arteries and disease activity and disability]. 145
[Eosinophilic fasciitis. A recently reported oligotopic connective tissue inflammation. A case report] 145
Cardiac involvement in undifferentiated connective tissue disease at risk for systemic sclerosis (otherwise referred to as very early-early systemic sclerosis): a TDI study 144
Low-dose aspirin as primary prophylaxis for cardiovascular events in systemic lupus erythematosus: A long-term retrospective cohort study 143
"To be or not to be," ten years after: evidence for mixed connective tissue disease as a distinct entity. 142
[A comparison between the Simplified Disease Activity Index (SDAI) and the Disease Activity Score (DAS28) as measure of response to treatment in patients undergoing different therapeutic regimens]. 141
[Absolute and relative increase in Leu-11b+ cells in patients with systemic scleroderma] 141
[Italian consensus on the recommendations about the use of methotrexate for the treatment of rheumatic diseases with a focus on rheumatoid arthritis: results from the "3E initiative"]. 140
Polymorphism of immunoglobulin enhancer element HS1,2A: allele *2 associates with systemic sclerosis. Comparison with HLA-DR and DQ allele frequency 139
[Hypocomplementemia in systemic sclerosis]. 139
A genetic variation located in the promoter region of the UPAR (CD87) gene is associated with the vascular complications of systemic sclerosis 139
Peripheral blood T lymphocytes from systemic sclerosis patients show both Th1 and Th2 activation 138
A SCLERODERMA PATIENT WITH SWOLLEN AND TENDER JOINTS OF BOTH HANDS 138
[FRI0313] CYCLOPHOSPHAMIDE PULSE THERAPY IN THE TREATMENT OF SYSTEMIC SCLEROSIS-INTERSTITIAL LUNG DISEASE G. Abignano, M. Iudici, A. Petrillo, G. Cuomo, G. Valentini. Rheumatology Unit, Second University of Naples, Napoli, Italy Background: Cyclophosphamide (CYC) is currently used in the treatment of interstitial lung disease (ILD) in patients with systemic sclerosis (SSc). A recent meta-analysis1 (Nannini C et al), pooling data from studies based on different entry criteria, questions its usefulness. Objectives: To investigate the effectiveness of low dose pulse CYC (500 mg/dose) in the treatment of recently deteriorating SSc-ILD. Methods: 51 patients with SSc-ILD, all of them satisfying ACR criteria for the classification of the disease and presenting with a recent (<6 months) decrease (≥10% of the predictive value) of either Forced Vital Capacity (FVC) or Diffusing Lung Capacity for CO (DLCO), were enrolled in the study. All of them underwent a concurrent prednisone therapy (10 mg/daily). CYC was administered i.v. at a dose of 500 mg weekly. Total CYC dose ranged from 4.5 to 11.5 g (median 7.5). An increase of 10% in either FVC or DLCO was considered indicative of improvement; a change between <10% and >10% of stable disease; a decrease ≥10% of worsening. Results: 22 out of the 51 SSc patients (43.14%) resulted to improve at the end of the CYC course; 17 (33.33%) remained stable; 12 (23.53%) worsened. No patients withdrew CYC treatment because of side effects. Conclusion: Our study suggests that the effectiveness of CYC in SSc-ILD may depend on entry criteria. Actually about 76% of patients who had experienced a recent deterioration of lung function, suggesting active alveolitis, underwent improvement or stabilization of their disease in our study. References:[ol][li]Nannini C, West CP, Erwin PJ, Matteson EL. Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies. Arthritis Res Ther 2008, 10:R124.[/li][/ol]Disclosure of Interest: None declared Ann Rheum Dis 2009;68(Suppl3):460 Session: Scleroderma, myositis and related syndromes 138
PREVALENCE OF ANTIBODIES RECOGNAIZING CYCLIC CITRULLINATED PEPTIDE(anti CCP) IN PATIENTS WITH ULCERATIVE COLITIS 137
Low-dose intravenous cyclophosphamide in systemic sclerosis: an open prospective efficacy study in patients with early diffuse disease 135
[Epidemiology and risk factors in osteoarthritis: literature review data from "OASIS" study]. 134
Early systemic sclerosis: assessment of clinical and pre-clinical organ involvement in patients with different disease features 134
Systemic sclerosis could mask the presentation of psoriasis in a patient with symptomatic and bilateral sacroiliitis 134
Evaluation of cardiac structures and function in systemic sclerosis by Doppler echocardiography 133
Cardiac involvement in rheumatoid arthritis: an echocardiographic study 131
Osteopenia in systemic sclerosis. Evidence of a participating role of earlier menopause 131
ANTI-TOPOISOMERASE I (ANTI-SCL-70) AND CANCER IN SYSTEMIC SCLEROSIS. ARE THEY RELATED? 131
Anti-carbamylated protein antibodies and skin involvement in patients with systemic sclerosis: An intriguing association 131
The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: Derivation and validation of a preliminarily revised EUSTAR activity index 130
2013 classification criteria for systemic sclerosis: An american college of rheumatology/European league against rheumatism collaborative initiative 130
[Copernican revolution in the therapy of rheumatoid arthritis: the contribution of anti-TNFalpha drugs]. 127
ELF Score: A Validated Serum Test Strongly Predictive of Fibrosis in Systemic Sclerosis. 127
A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: a EUSTAR prospective study 126
Evidence for peripheral impaired glucose handling in patients with connective tissue diseases 126
RELAPSING POLYCHONDRITIS. AN HYSTOCHEMICAL STUDY BY LECTIN. 125
EUSTAR biobanking: recommendations for the collection, storage and distribution of biospecimens in scleroderma research 125
Low-dose pulse cyclophosphamide in interstitial lung disease associated with systemic sclerosis (SSc-ILD): Efficacy of maintenance immunosuppression in responders and non-responders. 125
[Rarity of sclerodermic renal crisis in the Italian population and the uncommon nature of the Vogt-Koyanagi-Harada syndrome in systemic sclerosis] 125
Low-dose aspirin as primary prophylaxis for cardiovascular events in rheumatoid arthritis: an Italian multicentre retrospective study 125
New strategies to address the pharmacodynamics and pharmacokinetics of tumor necrosis factor (TNF) inhibitors: A systematic analysis. 124
Glucocorticoids in systemic sclerosis: patients' beliefs and treatment adherence. 124
Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients 124
Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database 123
[Metabolic syndrome in inflammatory rheumatic diseases]. 123
Prevalence of anti-toxoplasma antibodies in patients with autoimmune diseases. 122
Alterazioni del sistema nervoso autonomo nella Sclerosi Sistemica (SSc). Risultati preliminari di uno studio sul rapporto con la severita della malattia 122
.Spectrum of cardiac involvement in systemic lupus erythematosus: echocardiographic, echo-Doppler observations and immunological investigation. 122
Non-Hodgkin's lymphoma in systemic sclerosis: case and literature review 122
European Scleroderma Study Group (ESCSG) Activity Index is correlated to quality of life measures both at admission and overtime 122
RELATIONSHIP OF THE 6-MIN WALKING TEST AND QUALITY OF LIFE 121
Tissue Doppler imaging in systemic sclerosis: A 3-year longitudinal study. 120
Quality of life as measured by the short-form 36 (SF-36) questionnaire in patients with early systemic sclerosis and undifferentiated connective tissue disease. 120
Brief report: Successful pregnancies but a higher risk of preterm births in systemic sclerosis: An Italian multicentric study. 120
Sub-Analysis of ELF Score Biomarkers Components Indicates a Specific Correlation with Different Organ Involvement in Systemic Sclerosis. 120
High IL-17E and Low IL-17C Dermal Expression Identifies a Fibrosis-Specific Motif Common to Morphea and Systemic Sclerosis. 119
Impaired exercise performance in systemic sclerosis and its clinical correlations 119
Low mortality rate in Italian rheumatoid arthritis patients from a tertiary center: Putative implication of a low anti-carbamylated protein antibodies prevalence 119
[The arthropathy of systemic sclerosis]. 118
Crioglobulinemia mista essenziale: prevalenza e caratteri della neuropatia periferica 118
Severe polymyositis due to Toxoplasma gondii in an adult immunocompetent patient: a case report and review of the literature. 118
ATHEROSCLEROSIS AND RHEUMATOID ARTHRITIS: EVALUATION OF INTIMA-MEDIA THICKNESS AND CORRELATION WITH INFLAMMATORY AND ATHEROGENIC MARKERS 118
Tocilizumab in the treatment of patients with rheumatoid arthritis in real clinical practice: Results of an Italian observational study 118
Effects and safety of rituximab in systemic sclerosis: An analysis from the European Scleroderma Trial and Research (EUSTAR) group 117
Early Systemic Sclerosis: Serum Profiling of Factors Involved in Endothelial, T-cell, and Fibroblast Interplay is Marked by Elevated Interleukin-33 Levels. 117
The incidence of cardiovascular events in Italian patients with systemic lupus erythematosus is lower than in North European and American cohorts: Implication of disease-associated and traditional risk factors as emerged by a 16-year retrospective GIRRCS study 117
Cell-free DNA in the plasma of patients with systemic sclerosis 116
Peripheral T lymphocytes from patients with early systemic sclerosis co-cultured with autologous fibroblasts undergo an oligoclonal expansion similar to that occurring in the skin 116
Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group 116
Thrombocytosis in progressive generalized sclerosis (scleroderma) and in other rheumatic diseases 116
VALIDATION OF THE SIMPLIFIED DISEASE ACTIVITY INDEX (SDAI) AND DAS28 AS MEASURE OF RESPONSE TO TREATMENT IN PATIENTS UNDERGOING DIFFERENT THERAPEUTIC REGIMENS 116
Diastolic abnormalities in systemic sclerosis: evidence for associated defective cardiac functional reserve 115
[Early systemic sclerosis: diagnostic criteria and work-up]. 115
Systemic sclerosis 115
Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study 114
Glucocorticoids in systemic sclerosis: weighing the benefits and risks - a systematic review 114
Twelve-month azathioprine as maintenance therapy in early diffuse systemic sclerosis patients treated for 1-year with low dose cyclophosphamide pulse therapy 114
Totale 22.688
Salva come PNG Salva come JPEG
Categoria #
all - tutte 127.841
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 127.841
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.312 0 0 93 103 738 103 106 162 134 120 201 552
2022/20234.527 430 195 113 303 394 316 112 297 1.767 184 204 212
2023/20242.785 195 131 182 285 626 109 189 230 130 161 228 319
2024/20255.492 125 162 120 195 715 859 820 459 612 803 381 241
2025/202616.130 526 591 852 893 1.372 9.137 815 518 686 342 234 164
2026/2027881 274 407 200 0 0 0 0 0 0 0 0 0
Totale 40.894